VK2735 Oral vs Injectable: Two Formats, One Molecule

Introduction

VK2735 comes in two forms that use the exact same molecule: a weekly injection and a daily pill. The injectable is further along and shows stronger weight loss in trials. The oral version is more convenient but, like all oral peptides, faces the challenge of surviving and absorbing through the gut. Neither is available yet, so this comparison is about understanding the strategy, not picking a prescription.

Here is how the two formats differ, why a company would develop both, and what the format choice means for the people who might eventually use it.

At TrimRx, we believe that understanding how a drug is delivered is part of understanding your options. If you want to see what is available to you right now, the free assessment quiz is an easy starting point.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Why Develop Two Formats of the Same Drug?

Viking is developing VK2735 as both an injectable and an oral pill because patients value choice, and the two formats serve different preferences. The molecule is the same GLP-1/GIP dual agonist in both cases. The difference is delivery.

Quick Answer: VK2735 is being developed by Viking Therapeutics in two formats: a weekly injectable and a daily oral tablet, both using the same GLP-1/GIP molecule.

An injectable delivers the drug reliably into the bloodstream, which is why injectables in this class tend to show the largest weight loss numbers. An oral pill is easier to take and avoids needles, which matters a lot for adherence and for people who simply will not inject.

By pursuing both, Viking hedges its bet. If injectables remain the gold standard for potency, it has that. If the market shifts toward oral convenience, it has that too. Most companies pick one lane. VK2735’s two-lane approach is part of what makes it notable.

How Does the Injectable Format Perform?

The injectable is VK2735’s lead program and carries its best data. Its phase 2 obesity trial reported weight loss in the mid-teens percentage range at higher doses over roughly 13 weeks, a fast and steep response.

That speed is the headline. Reaching double-digit weight loss in about three months is aggressive compared with the 68 to 72 week designs of many obesity trials. Short trials cannot show where weight loss plateaus, but the early curve was strong.

The injectable is the format most likely to reach the market first if VK2735 succeeds, because it is more advanced and because injectables reliably deliver enough drug to drive results.

How Does the Oral Format Perform?

The oral version is earlier in development and faces the core challenge of all oral peptides: getting enough of the molecule absorbed through the digestive tract to work. Peptides are fragile and poorly absorbed by default.

Viking has reported early oral data and is advancing the program, but the oral format does not yet have the depth of results the injectable has. The expectation across the field is that oral peptide drugs deliver somewhat less drug than injectables, which can mean smaller weight loss or higher required doses.

If the oral VK2735 proves it can drive meaningful weight loss without injections, it would be a genuine advantage. That is still a question the data has to answer, not a settled fact.

Oral vs Injectable: The Core Tradeoff

The tradeoff is potency versus convenience. Injectables tend to deliver more drug more reliably, producing larger weight loss. Oral pills are easier and needle-free but usually absorb less, which can cap their effect.

For VK2735, the injectable carries the strong numbers and the oral carries the convenience promise. Which one matters more depends on the person. Someone focused on maximum weight loss may prefer the injectable. Someone who avoids needles may accept a somewhat smaller effect for a daily pill.

This same tradeoff defines the entire oral GLP-1 race, including orforglipron and oral semaglutide. It is the central design tension of the category.

Does the Format Change the Side Effects?

Both formats share the GLP-1/GIP side effect family: nausea, vomiting, diarrhea, constipation, and reduced appetite, worst during dose escalation. The mechanism is the same, so the type of side effects is similar.

Oral formats can produce more localized gastrointestinal effects in some cases because the drug passes through the gut directly, and dosing schedules differ between formats. Injectables deliver a steadier weekly exposure, while a daily pill creates a different exposure pattern.

Neither format has long-term safety data yet, since both are investigational. That is a key limitation no convenience advantage can offset.

When Might Each Format Be Available?

The injectable is more advanced and would likely reach the market first if phase 3 trials succeed and the FDA approves it, a process that takes years. The oral version is earlier and would follow later, if at all.

Neither has an approval or a confirmed launch date as of 2026. Pipeline timelines often slip, and trials can fail, so neither format should be treated as something to wait for.

The realistic stance is to watch both programs as they hit clinical milestones, while making current decisions based on approved drugs.

Key Takeaway: The oral version trades some potency for convenience, since oral peptide absorption is limited.

Which Format Would Suit Which Patient?

If both formats eventually launch, the injectable would suit people prioritizing maximum weight loss and comfortable with a weekly shot. The oral would suit people who strongly prefer a pill and will accept its tradeoffs.

This mirrors the existing market. Some patients do well on injectable semaglutide or tirzepatide. Others gravitate toward oral options like Rybelsus® or oral Wegovy®. Format preference is real and affects adherence, which affects results.

For now, this is a hypothetical choice. VK2735 is not available in either form, so the practical decision is between approved drugs that exist today.

What History Tells Us About Oral Versus Injectable

The semaglutide story is the best guide here. Injectable semaglutide came first and showed about 14.9% weight loss in STEP 1 (Wilding 2021, NEJM). Oral semaglutide followed, requiring careful dosing rules and generally needing higher milligram doses to approach similar effects because absorption is low.

That pattern is the template for VK2735. Expect the injectable to lead on potency and the oral to focus on convenience, with dosing engineered to close as much of the gap as possible. Whether the oral VK2735 matches its injectable cousin is the open question.

The lesson for patients is that “oral version” does not automatically mean “same results in a pill.” It means a different tradeoff that has to be judged on its own data once that data exists.

Why Convenience Changes Outcomes

Adherence is the quiet driver of weight loss success. A drug only works if you keep taking it, and format heavily influences that. Some people skip or quit injectables because of needle aversion, travel hassle, or storage concerns.

An effective oral VK2735 could improve real-world results simply by being easier to stick with, even if its peak efficacy is slightly lower than the injection. A modestly less potent drug taken consistently can beat a more potent one taken erratically.

This is why the format race matters beyond marketing. The best outcome is the one you actually sustain, which is why having both a shot and a pill option, as VK2735 aims to offer, is genuinely useful.

Your Path Forward with TrimRx

Whether VK2735 ends up as a shot, a pill, or both, it is not here yet. Approved treatment is. TrimRX offers compounded semaglutide and tirzepatide through a personalized telehealth program, with provider oversight and attention to muscle protection and nutrition.

If you are weighing injectable versus oral, that choice already exists among approved medications. TrimRX’s free assessment quiz can help you see whether a structured program, and which format, fits your life.

Bottom line: For treatment now, approved options like tirzepatide and semaglutide, including compounded versions through TrimRX, are the realistic choices.

FAQ

Is VK2735 a Pill or an Injection?

Both. Viking Therapeutics is developing VK2735 in two formats using the same molecule: a weekly injectable and a daily oral tablet. Neither is approved yet.

Which VK2735 Format Works Better?

The injectable carries the stronger phase 2 weight loss data and is more advanced. The oral version is earlier in development and, like all oral peptides, may deliver less drug due to limited absorption.

Why Develop Both Formats?

To offer choice. Injectables tend to be more potent, while oral pills are more convenient and needle-free. Developing both lets the drug compete in either preference.

Is the Oral VK2735 Available Now?

No. Both the oral and injectable formats are investigational and not approved or available as of 2026.

Do the Two Formats Have Different Side Effects?

They share the same GLP-1/GIP side effects since the molecule is identical. Exposure patterns differ between a daily pill and a weekly shot, but the side effect type is similar.

What Can I Take Instead While VK2735 Is in Development?

Approved options like tirzepatide and semaglutide are available now in both injectable and oral forms, including compounded versions through telehealth programs such as TrimRX.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.